New developments in Toll-like receptor targeted therapeutics

被引：150

作者：

Connolly, Dympna J. ^{[1
]}

O'Neill, Luke A. J. ^{[1
]}

机构：

[1] Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin 2, Ireland

来源：

CURRENT OPINION IN PHARMACOLOGY | 2012年 / 12卷 / 04期

基金：

爱尔兰科学基金会;

关键词：

MYCOBACTERIUM-BOVIS BCG; CELL-WALL SKELETON; ISCHEMIA/REPERFUSION INJURY; HEALTHY-VOLUNTEERS; CRYSTAL-STRUCTURE; IMMUNE-RESPONSES; INNATE IMMUNITY; CLINICAL-TRIAL; DOUBLE-BLIND; HEPATITIS-B;

D O I：

10.1016/j.coph.2012.06.002

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Toll-like receptors (TLRs) play a crucial role in host defence and inflammation. Given that a significant amount of evidence implicates TLRs in the pathogenesis of immune diseases and cancer, and their activation occurs early in the inflammatory cascade, they are attractive targets for novel therapeutic agents. Potential therapeutics include TLR-targeted antibodies, small molecules and nucleic acid based drugs. Agonists are being tested in vaccines against hepatitis C and influenza as well as in allergic rhinitis and certain cancers. Antagonists are being tested in ischemia/reperfusion injury, systemic lupus erythematosus and psoriasis. The prospect of targeting TLRs in multiple pathologies continues to hold much promise.

引用

页码：510 / 518

页数：9

共 68 条

[1]

Synthetic agonists of Toll-like receptors 7, 8 and 9 [J].

Agrawal, S. ;

Kandimalla, E. R. .

BIOCHEMICAL SOCIETY TRANSACTIONS, 2007, 35 :1461-1467

[2]

The Search for Effective Therapy for Sepsis Back to the Drawing Board? [J].

Angus, Derek C. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (23) :2614-2615

[3]

Treatment With OPN-305, a Humanized Anti-Toll-Like Receptor-2 Antibody, Reduces Myocardial Ischemia/Reperfusion Injury in Pigs [J].

Arslan, Fatih ;

Houtgraaf, Jaco H. ;

Keogh, Brian ;

Kazemi, Kushan ;

de Jong, Renate ;

McCormack, William J. ;

O'Neill, Luke A. J. ;

McGuirk, Peter ;

Timmers, Leo ;

Smeets, Mirjam B. ;

Akeroyd, Lars ;

Reilly, Mary ;

Pasterkamp, Gerard ;

de Kleijn, Dominique P. V. .

CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2012, 5 (02) :279-287

[4]

Myocardial Ischemia/Reperfusion Injury Is Mediated by Leukocytic Toll-Like Receptor-2 and Reduced by Systemic Administration of a Novel Anti-Toll-Like Receptor-2 Antibody [J].

Arslan, Fatih ;

Smeets, Mirjam B. ;

O'Neill, Luke A. J. ;

Keogh, Brian ;

McGuirk, Peter ;

Timmers, Leo ;

Tersteeg, Claudia ;

Hoefer, Imo E. ;

Doevendans, Pieter A. ;

Pasterkamp, Gerard ;

de Kleijn, Dominique P. V. .

CIRCULATION, 2010, 121 (01) :80-90

[5]

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies [J].

Barochia, Amisha ;

Solomon, Steven ;

Cui, Xizhong ;

Natanson, Charles ;

Eichacker, Peter Q. .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (04) :479-494

[6]

Treatment of lupus-prone of TLR7 and TLR9 leads to mice with a dual inhibitor reduction of autoantibody production and amelioration of disease symptoms [J].

Barrat, Franck J. ;

Meeker, Thea ;

Chan, Jean H. ;

Guiducci, Cristiana ;

Cofftnan, Robert L. .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 (12) :3582-3586

[7]

A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass [J].

Bennett-Guerrero, Elliott ;

Grocott, Hilary P. ;

Levy, Jerrold H. ;

Stierer, Kevin A. ;

Hogue, Charles W. ;

Cheung, Albert T. ;

Newman, Mark F. ;

Carter, Alison A. ;

Rossignol, Daniel P. ;

Collard, Charles D. .

ANESTHESIA AND ANALGESIA, 2007, 104 (02) :378-383

[8]

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV [J].

Bergmann, J. F. ;

de Bruijne, J. ;

Hotho, D. M. ;

de Knegt, R. J. ;

Boonstra, A. ;

Weegink, C. J. ;

van Vliet, A. A. ;

van de Wetering, J. ;

Fletcher, S. P. ;

Bauman, L. A. ;

Rahimy, M. ;

Appleman, J. R. ;

Freddo, J. L. ;

Janssen, H. L. A. ;

Reesink, H. W. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (04) :443-453

[9]

Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2 [J].

Biragyn, A ;

Ruffini, PA ;

Leifer, CA ;

Klyushnenkova, E ;

Shakhov, A ;

Chertov, O ;

Shirakawa, AK ;

Farber, JM ;

Segal, DM ;

Oppenheim, JJ ;

Kwak, LW .

SCIENCE, 2002, 298 (5595) :1025-1029

[10]

Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7 [J].

Boonstra, Andre ;

Liu, Bi-Sheng ;

Groothuismink, Zwier M. A. ;

Bergmann, Jilling F. ;

de Bruijne, Joep ;

Hotho, Daphne M. ;

Hansen, Bettina E. ;

van Vliet, Andre A. ;

de Rooij, Jeroen van de Wetering ;

Fletcher, Simon P. ;

Bauman, Lisa A. ;

Rahimy, Mohamad ;

Appleman, James R. ;

Freddo, James L. ;

Reesink, Hendrik W. ;

de Knegt, Robert J. ;

Janssen, Harry L. A. .

ANTIVIRAL THERAPY, 2012, 17 (04) :657-667

← 1 2 3 4 5 6 7 →